1.Syed Ali Rizvi, Wajahat Syed, and Ravi Shergill. Approach to pseudomyxoma peritonei. World J Gastrointest Surg. 2018 10(5): 49– 56.
2. Amini A, Masoumi-Moghaddam S, Ehteda A et al. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects. Orphanet Journal of Rare Diseases 2014, 9:71
3.Ronnett BM, Zahn CM, Kurman RJ,et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei” Am J Surg Pathol. 1995; 19:1390–1408.
4.Carr NJ, Sobin LH . Tumours of the appendix. In: Bosman FT, Carneiro F, Hruban RH, Theise ND , eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC Press; 2010:122–125. World Health Organization Classification of Tumours; vol 3.
5. Sugarbaker PH. Pseudomyxoma peritonei. Cancer Treat Res. 1996; 81:105-19.
6.Gupta A, Chandrakumaran K, Cecil TD et al. Tumour grade and complete tumour removal affects survival after cytoreductive surgery and HIPEC for Pseudomyxoma Peritonei (PMP) of appendiceal origin. PMI Basingstoke Basingstoke and North Hampshire Hospital. 2014. Available from: https://www.acpgbi.org.uk/content/uploads/2015/11/SP016-Colorectal-Cancer-Gupta-Tripartite-2014.pdf.
7. Chua TC, Yan TD, Saxena A et al.Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009; 249:900–907.
8.Lord AC, Shihab O, Chandrakumaran K et al. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours. Eur J Surg Oncol. 2015;41:396–399
9.Yan TD, Black D, Savady R et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484–492.
10.Qi ZH, Cai S, Li JC Ultrasonographic Features of Pseudomyxoma Peritonei and TheirComparison with Computed Tomographic Findings. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2015 Aug;37(4):424-9.
11.Liang, L., Wang, W., Zhou, N. et al. Value of preoperative ultrasound in evaluating the peritoneal cancer index of pseudomyxoma peritonei. World J Surg Onc 17, 192 (2019)
12.Fonseca C, Carvalho S, Cunha TM et al. The many faces of pseudomyxoma peritonei: a radiological review based on 30 cases. Radiol Bras. 2019 Nov/Dez;52(6):372–377.
13.Russell N. Low, Robert M. Baroneet al. Mucinous Appendiceal Neoplasms: Preoperative MR Staging and Classification Compared with Surgical and Histopathologic Findings. American Journal of Roentgenology 2008 190:3, 656-665.
14.Sugarbaker PH. Surgical responsibilities in the management of peritoneal carcinomatosis. J Surg Oncol. 2010 Jun 15;101(8):713-24.
15.Benhaim L, Faron M, Gelli M et al Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei,Surgical Oncology,Volume 29, 2019, Pages 78-83.